Les attentes industrielles en Europe

1
Les attentes industrielles en Europe Dr. Johan
Vanhemelrijck Secrétaire Général -
EuropaBio Forum Européen PLANTES, INNOVATIONS,
INDUSTRIES 30 novembre 2005 Amiens (France)
2
Biotechnology The Invisible RevolutionIndustry
expectation.

• Predictable rules in research stimulation
• Robust product evaluation and approval stimulate
  entrepreneurship.
• The resolution of the GMO debate to be able to
  invest in Bio-energy and Bio-products.
• Positive discrimination of environment friendly
  produced products.
• Positive discrimination for life saving and real
  cures.
• Positive discrimination of new therapy avenues
  for rare diseases.
• Positive discrimination of YIC/YLC investments.

3
Risk Aversion to Biotech
4
US Versus EU
2003 figures .
-- 1976 Companies -- 94000 employees - 35000 in
RD -- 6 billion in RD -- 750 million in
Venture Capital -- 1 billion in debt financing
-- 1830 Companies -- 172,400 employees -- 16.4
billion in RD -- 2.1 billion in Venture
Capital -- 4.3 billion in debt financing
Source Critical I
5
Arts and skills of the bio-entrepreneurMinimize
entrepreneurial risk, maximize societal value
Research risks
IPR risks
VALUE
Financial risks
Regulatory risks
Market risks
RISK
TIME LINE
6
Product Approval Regulations must be Predictable
7
BioForecasting
8
The Invisible Revolution
9
Healthcare Biotech
10
Healthcare Biotech Progress

• Causative agents
• Real cure
• Less side effects
• Wound healing
• Genetic tests
• Genetic deficiencies
• Disease mechanisms
• Rare Diseases
• Etc

11
Agriculture and Biotech
12
White Biotech an industrial revolution
13
Secure Food Supplies, and more Examples
14
Building an Industry on the Back of Life Sciences
15
DECISIONSdecisionsdecisions

• All entrepreneurs take decisions based on
• What they know (experience, proof of principle,
  finance)
• What they consider is needed (market, society)
• What they expect to provide (service product,
  success)
• All entrepreneurs should be used to easily adapt
  to new challenges and turn them into
  opportunities.
• 2000 companies are Young and Innovative, why call
  them SMEs? Give them support in a new statute.
• In Biotechnology few come to the regulatory
  product approval process.
• Therefore

16
Call to Arms